🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tired of tedious CME credits and expensive board exam prep? Download #OncoBlast now to earn FREE CME/MOC with board review questions: bit.ly/3YI4qyZ🏆 #MedEd #HemOnc #Oncology #OncTwitter

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… The V Foundation for Cancer Research Chris Johnson Foundation Inc.

Hot off the press- great work by our 2nd year fellow Matthew Siskin describing the role of CDK4/6 inhibition in prostate cancer! David Wise MD PhD MDPI urldefense.com/v3/__https://w…$

🚨SBRT+ADT for oligometastatic #prostatecancer 👉RADIOSA trial The Lancet Oncology 💉6 months of ADT prolonged time to clinical progression from 15 to 32 months 🔗shorturl.at/0p062

📑Managing ccRCC With Sarcomatoid or Rhabdoid Differentiation: Distinct Subtypes Warrant Distinct Treatment – ASCO Daily News, by Hongchao He & colleagues MD Anderson Cancer Center 🔗dailynews.ascopubs.org/do/managing-cc… Pavlos Msaouel Matt Campbell MD, MS Eric Jonasch Andrew Johns, MD Andy Hahn Kidney Cancer

NYU Langone Health pioneers a first-in-the-nation robotic surgery to treat urethral damage caused by radiation. Using small bowel tissue & microsurgery, Lee Zhao offers a game-changing alternative to bladder removal. Learn more: physicianfocus.nyulangone.org/a-new-option-f…

Great to hear my colleague Xiuning Le MD PhD MD Anderson Cancer Center review the first line treatment landscape for patients with EGFR positive NSCLC. ▫️Knowing exactly what EGFR mutation you have is key ▫️There are now multiple FDA approved options for 1L treatment GRACE

👇The Clinical Cancer Research cover below is a #RenalMedullaryCarcinoma cell expressing MUC16 (CA-125) in green and actin red with overlapping regions in yellow. Photo taken by Menuka Karki #MsaouelLab and also featured in our art contest led by Eleonora Dondossola,PhD Full article: aacrjournals.org/clincancerres/…

2025 prostate cancer staging from National Comprehensive Cancer Network (NCCN) and AJCC 8th edition Major change in 2025 NCCN vs prior years: Very high risk disease is now per STAMPEDE criteria (not Hopkins)

Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest IBCG consensus in European Urology offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate

📘mCRPC guideline update ASCO Journal of Clinical Oncology 👉doi.org/10.1200/JCO-25… OncoAlert #cancer #oncology #MedX #ASCO25

🚨 THRILLED to welcome my friend and colleague Manuel Hidalgo 🇪🇸 🇺🇸 as the co-director of the new GI Cancer Center at Perlmutter Cancer Center at NYU Langone Health NYU Langone Health Manny & I collaborated for over a decade in #PancreaticCancer research at Hopkins, so I am delighted to get the band back together in NYC! 🗽

🗣️Bladder Cancer Oral Abstracts #ASCO25 👉Abs4503: Dr Tom Powles presenting ctDNA pts w/ MIBC on perioperative #durvalumab from #NIAGARA N = 1063 cisplatin-eligible pts with MIBC (cT2-T4aN0/1M0) Biomarker Eligible = 462 💉#Durva + NAC (GC) x4 ->RC -> #Durva x 8 cycles (D)

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

JAMA Patient Page: What Are Testicular Germ Cell Tumors? JAMA OncoAlert Oncology Brothers Testicular Cancer Testicular Cancer Society Youth Cancer Europe doi:10.1001/jama.2025.5884

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospective study Urologic Oncology asks: does VIGOROUS exercise raise risk? 👉pubmed.ncbi.nlm.nih.gov/40617795/ #MsaouelLab

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Want a Sunday morning reading with a sip of coffee? Here is one (in press) for #PCSM enthusiasts! sciencedirect.com/science/articl… Always grateful for the support and motivation from Daniel E Spratt even during tough times and Yilun Sun for teaching me new things every time!!

Justin Lebenthal, MD explaining the basics of prostate cancer. Helpful for anyone who is, or is supporting, someone with a new diagnosis! Prostate Cancer UK Prostate Cancer Foundation ZERO Prostate Cancer ProstateCancerResearch ASCO